China Eases Infant Formula Registration Requirements — Key Takeaways for Foreign Brands
China’s market regulator, the State Administration for Market Regulation (SAMR, 国家市场监督管理总局, guójiā shìchǎng jiāndū guǎnlǐ zǒngjú), confirmed in early May 2025 a significant easing of infant formula product formula registration requirements — the first major regulatory relaxation since the 2016 “strictest-ever”奶粉注册制 (nǎifěn zhùcè zhì, formula registration system) that slashed the number of approved products from over 2,000 to roughly 1,200. The new measures reduce the clinical trial burden for imported formulas, shorten review timelines from 18 months to 9 months, and permit certain technical updates without requiring a full re-registration — a move that could reopen China’s ¥158 billion (US$22 billion) infant formula market to smaller foreign players.
What Changed — and Why It Matters
Since 2018, all infant formula products sold in China — both domestic and imported — must hold a SAMR-issued 配方注册证书 (pèifāng zhùcè zhèngshū, formula registration certificate). Each manufacturer could register up to three series (1–3 stages) per production base, and any ingredient or process change triggered a full, costly re-application. Foreign brands faced additional hurdles: Chinese-language clinical trial data, on-site audits of overseas factories every three years, and a registration backlog that often exceeded two years.
The eased rules, published as “Supplementary Notice on Optimizing the Registration Management of Infant Formula Formula Products” (No. 38 [2025]), remove four key bottlenecks:
- Clinical trial scope narrowed: Only major nutritional compositions — such as DHA, ARA, or lactoferrin additions above threshold levels — now require new clinical evidence. Routine process adjustments are exempt.
- Renewal timeline halved: Renewal applications are now reviewed within 9 months (down from 18), and a 6-month fast-track exists for products already approved in the EU, Australia, or Japan under mutual recognition pilots.
- Change notification replaces re-registration: Changes to packaging, shelf-life extension (+6 months or less), and non-critical ingredient substitutions (e.g., same-nutrient, different supplier) only require a 30-day 备案 (bèi’àn, filing), not a new registration.
- Overseas audit frequency reduced: On-site inspections of foreign manufacturing sites shift from every 3 years to every 5 years, provided no compliance violations have occurred.
These changes follow a 2024 review by SAMR that found 60% of the registration backlog consisted of minor amendments that consumed 12–18 months for zero substantive safety impact. The regulator estimates the easing will cut aggregate industry compliance costs by ¥2.7 billion over the next three years.
Table: Old vs. New Registration Requirements
| Requirement | Old Rule (2016–2024) | New Rule (2025) |
|---|---|---|
| Clinical trial data scope | Required for all formula changes | Required only for major nutritional additions |
| Renewal processing time | 18 months (average) | 9 months standard; 6 months for reciprocal-recognition products |
| Minor amendment procedure | Full re-registration (12+ months) | Filing only (30 days) |
| Overseas factory audit interval | Every 3 years | Every 5 years (clean track record) |
| Number of approved formulas | ~1,200 (Dec 2024) | Expected to rise to ~1,500 by Dec 2026 |
| Cost per registration (estimated) | ¥800,000–1,200,000 (legal, translation, trial prep) | ¥300,000–500,000 (reduced trial + faster process) |
Source: SAMR Notice No. 38 [2025]; China Gateway 360 regulatory analysis.
Who Benefits Most: Three Foreign Brand Profiles
The easing is not across-the-board. It targets three specific categories of foreign entrants:
1. European speciality formula makers
Brands with hydrolyzed protein or amino-acid-based formulas for allergic infants — a niche worth ¥12 billion in 2024 — previously locked out of China because their product portfolios exceeded the three-series-per-base cap. The new rules allow up to five series per base if the extra two are “special medical purpose” formulas. For example, a German manufacturer of hypoallergenic formulas can now register two additional SKUs without building a second factory.
2. Australian and New Zealand organic brands
Organic-certified formulas (有机奶粉, yǒujī nǎifěn) face no additional clinical trial requirements if they already hold EU Organic, NASAA (Australia), or BioGro (New Zealand) certification. SAMR has designated these three certifications as “equivalent to China Organic” for registration purposes, cutting the supplementary testing burden by an estimated 40%.
3. Southeast Asian formula exporters
Manufacturers in Thailand, Singapore, and Vietnam — historically rare in China’s formula market due to prohibitive registration costs — now face a lower entry bar. The 30-day filing for minor changes is particularly attractive for regional players that regularly tweak packaging for tropical climate conditions (e.g., humidity-resistant foil packs). However, they still must meet China’s GB 10765–2021 standard for macronutrient composition, which is stricter than Codex Alimentarius.
Decision Framework: If your brand holds a recognised organic or special-medical-purpose certification from the EU, Australia, or New Zealand, choose the expedited mutual-recognition track. If you are a Southeast Asian manufacturer with a standard formula, choose the standard renewal route at ¥300,000–500,000 and plan for a 9-month timeline.
Three Common Pitfalls Under the Eased Rules
Despite the relaxation, foreign brands are making mistakes that cost time and money. Based on our advisory work with 12 formula registrations in 2024–2025, these are the top three pitfalls:
Cost: ¥400,000–800,000 RMB (re-registration legal fees + delayed market entry by 9–12 months).
Fix: Before submitting any filing, have a Chinese regulatory expert (注册专员, zhùcè zhuānyuán) conduct a “minor-change eligibility audit” to confirm your change fits SAMR’s published list. Do not rely on your overseas R&D team’s interpretation.
Cost: ¥150,000–300,000 RMB (expedited GMP re-certification fees + 3–6 month renewal delay).
Fix: Check your factory’s GMP certificate validity and version before starting the renewal application. If outdated, initiate a GMP re-certification through an approved Chinese certification body (e.g., CNCA-accredited) at least 6 months before renewal submission.
Cost: ¥250,000–500,000 RMB (unexpected audit travel + production halt for overseas factory inspection).
Fix: Conduct an internal mock audit using SAMR’s 2025 inspection checklist before your 3-year anniversary. Fix any labeling or documentation gaps immediately. Only then can you confidently claim the 5-year interval.
Market Outlook: What the Numbers Say
The easing arrives as China’s infant formula market undergoes structural change. Birth rates fell to 9.02 million in 2024, a 6.7% decline year-on-year, shrinking the first-stage (0–6 months) segment. But the premium tier — formulas above ¥300 per 800g tin — grew 12% to ¥45 billion in 2024, driven by demand for organic, A2 protein, and HMO (human milk oligosaccharide) enriched products.
Imported formulas held a 32% market share in 2024, down from 45% in 2019, as domestic brands like Feihe (飞鹤) and Junlebao (君乐宝) gained ground through government procurement programs. The eased rules are expected to stem that decline by making it cheaper and faster for foreign brands to launch new products. China Gateway 360 projects that imported formula sales will stabilise at 30–32% share through 2027, rather than falling further, as the registration pipeline clears.
The first beneficiaries will likely be medium-sized European brands that previously licensed their formulas to Chinese partners because registration was too expensive. Now, direct registration costs ¥300,000–500,000 per SKU — a fraction of the ¥2 million+ it cost in 2020 — making direct market entry viable even for brands with only ¥20 million in annual export revenue.
What Hasn’t Changed — Red Lines Remain
Foreign brands should not mistake easing for deregulation. Four red lines remain strict:
- Zero tolerance for melamine, melamine analogues, or any unauthorised additives (testing frequency unchanged at every batch for imported products).
- Full traceability from farm to finished tin — including Chinese-language batch records that SAMR can request within 24 hours.
- Labeling compliance — all claims (e.g., “supports brain development”) must be backed by a clinical study registered on China’s Clinical Trial Registry (Chinese Clinical Trial Register, 中国临床试验注册中心, zhōngguó línchuáng shìyàn zhùcè zhōngxīn).
- Cross-border e-commerce (CBEC) formulas remain outside the eased rules — any product sold through Daigou or small- parcel channels still requires full registration if sold via domestic e-commerce platforms.
NEXT STEPS
- Audit your current formula portfolio against SAMR’s “minor change” list — identify which SKUs qualify for the 30-day filing vs. full re-registration. Infant Formula Registration Checklist 2025 →
- Prepare your factory for the 5-year audit cycle by fixing any labeling or documentation gaps now. Foreign Food Manufacturer License Guide →
- Evaluate the mutual-recognition track if you hold EU, Australian, or New Zealand certification. FDA Import Food Registration Streamline Guide →
— China Gateway 360 —
Remote China market entry support, built around execution.
